133 related articles for article (PubMed ID: 35692105)
1. Taxane-induced neuropathy: How serious is this problem for patients with early breast cancer?
Nicolae R; Uccellini A; Siderov J; Mellerick A; Wong V; Yeo B
Asia Pac J Clin Oncol; 2023 Apr; 19(2):e118-e127. PubMed ID: 35692105
[TBL] [Abstract][Full Text] [Related]
2. Incidence of taxane-induced peripheral neuropathy receiving treatment and prescription patterns in patients with breast cancer.
Song SJ; Min J; Suh SY; Jung SH; Hahn HJ; Im SA; Lee JY
Support Care Cancer; 2017 Jul; 25(7):2241-2248. PubMed ID: 28204996
[TBL] [Abstract][Full Text] [Related]
3. Serum sodium ions and chloride ions associated with taxane-induced peripheral neuropathy in Chinese patients with early-stage breast cancer: A nation-wide multicenter study.
Zhai J; Sun X; Zhao F; Pan B; Li H; Lv Z; Cao M; Zhao J; Mo H; Ma F; Xu B
Breast; 2023 Feb; 67():36-45. PubMed ID: 36586272
[TBL] [Abstract][Full Text] [Related]
4. Persistent taxane-induced neuropathy in elderly patients treated for localized breast cancer.
Pabst L; Velten M; Fischbach C; Kalish M; Pflumio C; Pivot X; Petit T
Breast J; 2020 Dec; 26(12):2376-2382. PubMed ID: 33307596
[TBL] [Abstract][Full Text] [Related]
5. Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African Americans.
Schneider BP; Lai D; Shen F; Jiang G; Radovich M; Li L; Gardner L; Miller KD; O'Neill A; Sparano JA; Xue G; Foroud T; Sledge GW
Oncotarget; 2016 Dec; 7(50):82244-82253. PubMed ID: 27732968
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and Tolerability of Nab-paclitaxel in Younger versus Elderly Patients With Metastatic HR-positive/HER2-negative Breast Cancer: Results From the Noninterventional, Prospective Study NABUCCO.
Potthoff K; Stötzer O; Söling U; Hansen R; Harde J; Dille S; Nusch A; Marschner N
Clin Breast Cancer; 2020 Jun; 20(3):e315-e326. PubMed ID: 32273207
[TBL] [Abstract][Full Text] [Related]
7. A Multimodal Approach to Discover Biomarkers for Taxane-Induced Peripheral Neuropathy (TIPN): A Study Protocol.
Sharma A; Johnson KB; Bie B; Rhoades EE; Sen A; Kida Y; Hockings J; Gatta A; Davenport J; Arcangelini C; Ritzu J; DeVecchio J; Hughen R; Wei M; Thomas Budd G; Lynn Henry N; Eng C; Foss J; Rotroff DM
Technol Cancer Res Treat; 2022; 21():15330338221127169. PubMed ID: 36172750
[No Abstract] [Full Text] [Related]
8. Risk factors for taxane-induced peripheral neuropathy in patients with breast cancer.
Liang C; Zhang Y; Chen QY; Chen WF; Chen MZ
Asia Pac J Clin Oncol; 2024 Apr; 20(2):220-227. PubMed ID: 36658674
[TBL] [Abstract][Full Text] [Related]
9. Taxane-Induced Peripheral Neuropathy: Objective and Subjective Comparison Between Paclitaxel and Docetaxel in Patients With Breast Cancer.
Chan YN; Jheng YW; Wang PJ; Chen CY; Lin MW; Wang YJ
Clin J Oncol Nurs; 2019 Oct; 23(5):494-501. PubMed ID: 31538967
[TBL] [Abstract][Full Text] [Related]
10. Taxane-induced peripheral neuropathy and quality of life in breast cancer patients.
Salehifar E; Janbabaei G; Alipour A; Tabrizi N; Avan R
J Oncol Pharm Pract; 2020 Sep; 26(6):1421-1428. PubMed ID: 31937190
[TBL] [Abstract][Full Text] [Related]
11. Impact of persistent peripheral neuropathy on health-related quality of life among early-stage breast cancer survivors: a population-based cross-sectional study.
Engvall K; Gréen H; Fredrikson M; Lagerlund M; Lewin F; Åvall-Lundqvist E
Breast Cancer Res Treat; 2022 Oct; 195(3):379-391. PubMed ID: 35941422
[TBL] [Abstract][Full Text] [Related]
12. Taxane and epothilone-induced peripheral neurotoxicity: From pathogenesis to treatment.
Tamburin S; Park SB; Alberti P; Demichelis C; Schenone A; Argyriou AA
J Peripher Nerv Syst; 2019 Oct; 24 Suppl 2():S40-S51. PubMed ID: 31647157
[TBL] [Abstract][Full Text] [Related]
13. Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199.
Schneider BP; Li L; Radovich M; Shen F; Miller KD; Flockhart DA; Jiang G; Vance G; Gardner L; Vatta M; Bai S; Lai D; Koller D; Zhao F; O'Neill A; Smith ML; Railey E; White C; Partridge A; Sparano J; Davidson NE; Foroud T; Sledge GW
Clin Cancer Res; 2015 Nov; 21(22):5082-5091. PubMed ID: 26138065
[TBL] [Abstract][Full Text] [Related]
14. Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients.
Tanabe Y; Shiraishi S; Hashimoto K; Ikeda K; Nishizawa D; Hasegawa J; Shimomura A; Ozaki Y; Tamura N; Yunokawa M; Yonemori K; Takano T; Kawabata H; Tamura K; Fujiwara Y; Shimizu C
BMC Cancer; 2020 Apr; 20(1):325. PubMed ID: 32295642
[TBL] [Abstract][Full Text] [Related]
15. Cytochrome P450 Oxidoreductase (POR) Associated with Severe Paclitaxel-Induced Peripheral Neuropathy in Patients of European Ancestry from ECOG-ACRIN E5103.
Shen F; Jiang G; Philips S; Gardner L; Xue G; Cantor E; Ly RC; Osei W; Wu X; Dang C; Northfelt D; Skaar T; Miller KD; Sledge GW; Schneider BP
Clin Cancer Res; 2023 Jul; 29(13):2494-2500. PubMed ID: 37126018
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci.
Sucheston-Campbell LE; Clay-Gilmour AI; Barlow WE; Budd GT; Stram DO; Haiman CA; Sheng X; Yan L; Zirpoli G; Yao S; Jiang C; Owzar K; Hershman D; Albain KS; Hayes DF; Moore HC; Hobday TJ; Stewart JA; Rizvi A; Isaacs C; Salim M; Gralow JR; Hortobagyi GN; Livingston RB; Kroetz DL; Ambrosone CB
Pharmacogenet Genomics; 2018 Feb; 28(2):49-55. PubMed ID: 29278617
[TBL] [Abstract][Full Text] [Related]
17. Current methods for the assessment and management of taxane-related neuropathy.
Smith EM
Clin J Oncol Nurs; 2013 Feb; 17 Suppl():22-34. PubMed ID: 23360700
[TBL] [Abstract][Full Text] [Related]
18. Incidence, description, predictors, and consequences of persistent taxane-induced peripheral neuropathy.
Hertz DL
Curr Opin Support Palliat Care; 2024 Mar; 18(1):30-38. PubMed ID: 38126251
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics of taxane-induced neurotoxicity in breast cancer: Systematic review and meta-analysis.
Guijosa A; Freyria A; Espinosa-Fernandez JR; Estrada-Mena FJ; Armenta-Quiroga AS; Ortega-Treviño MF; Catalán R; Antonio-Aguirre B; Villarreal-Garza C; Perez-Ortiz AC
Clin Transl Sci; 2022 Oct; 15(10):2403-2436. PubMed ID: 35892315
[TBL] [Abstract][Full Text] [Related]
20. Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Tolaney SM; Guo H; Pernas S; Barry WT; Dillon DA; Ritterhouse L; Schneider BP; Shen F; Fuhrman K; Baltay M; Dang CT; Yardley DA; Moy B; Marcom PK; Albain KS; Rugo HS; Ellis MJ; Shapira I; Wolff AC; Carey LA; Overmoyer B; Partridge AH; Hudis CA; Krop IE; Burstein HJ; Winer EP
J Clin Oncol; 2019 Aug; 37(22):1868-1875. PubMed ID: 30939096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
